Navigation Links
Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report

Branded Pharmaceutical companies can expect to see sales drops of up to 70

percent after patent expiration from Generic competition

NEW YORK, LONDON and TOKYO, July 14 /PRNewswire/ -- Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of this year, Branded drug patents accounting for sales of more than $80 Billion will expire, resulting in major losses in company profits. In the United States, the Generics Industry claims more than 50 percent of all prescriptions filled. Even in Japan, where Generics penetration is notoriously low, changes are afoot. The government has taken note from countries like the U.S. and instructed all national hospitals to actively use Generics. Now, in Japan, doctors and pharmacists can collect additional fees for prescribing and dispensing Generics. Combine these trends with a growing number of Japanese blockbuster drugs facing patent expiration and the Generics penetration rate is poised to expand in coming years, even in the 'Generics-proof' Japanese market. To address this globally alarming issue, Eularis announces today the availability of their new report, "How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation."

*(PHOTO Link:

*(Photo Caption: Dr. Andree K. Bates, President of Eularis.)

Written for CEO's, Marketing Executives and Sales Executives, this report uncovers the factors working for Generics growth and the barriers against it, offering secrets the Generics Industry doesn't want you to know. The report includes case studies of how to analyze where weaknesses exist within your Generics competitors and what to do about it. The report discusses appropriate tactics to improve competitiveness with Generics and demonstrates implementation methods and issues. The report delves into specific marketing situations -- such as USA, Europe and Japan -- and identifies issues relevant to each market.

"Pharmaceutical companies need to seriously reconsider their approach to solving the Generics problem," commented Dr. Andree K. Bates, author of the report and President of Eularis. "The Generics threat is very real, and growing. However, Generics are not all-powerful, invulnerable competitors. To truly mount an effective defense against Generics, companies must realize what's hurting Generic growth and use these issues to develop a path that works to help Branded Pharma."

Effective defense strategies exist that employ a variety of reactive and proactive measures. More importantly, the report shows that the Generics Industry is facing some powerful challenges and damaging growing pains in its path towards dominance. To truly understand the Pharma Industry's ability to deflect the Generics threat, companies must know the best defense strategies. However, they also must know the reality of what's happening in the Generics realm.

Bates has gained wide recognition within the international Pharmaceutical Industry for her expertise in Pharmaceutical Marketing Analysis. In addition to this and other must-have reports for Pharmaceutical Industry marketers, she has authored many articles in peer-reviewed journals and several chapters in books on Pharmaceutical Analytics.

To purchase the Eularis report, "How to Plan an Effective Generics Defense Strategy: Planning, Tactics and Implementation," visit: or, for more information about Eularis, visit


Eularis provides sophisticated Pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches, which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis' proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps Pharmaceutical marketing teams to quickly plan, measure, validate and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, Managed Care analytics, patient compliance solutions and Generics defense analysis strategies. With offices in London, New York and Tokyo, the company has developed significant experience in the global Pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Eularis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eularis to Address Making the Right Research Decision for ROI
2. Eularis Exposes Hidden Barriers to Patient Adherence With New Pharmaceutical Industry Report
3. MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London
4. MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP?
5. Eularis Releases Update of Its Comprehensive Report on Maximizing the Bottom Line in Pharmaceutical Marketing
6. Eularis Announces New Corporate Name and Expanded Product Offerings
7. Survey: Most effective dental braces are least attractive
8. Study Measures Real-World Comparative Effectiveness of Asthma Controller Medications
9. New Report Examines Pharmaceutical Sales Force Effectiveness
10. How effective are dental referrals by primary care physicians?
11. Smoke-Free Policies Prove Effective
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... Purdue University announced Tuesday (Oct. 13) ... aimed at enhancing Purdue’s life sciences research and graduate education. The initiative comes ... The investment will result in cohesive efforts across several colleges and is designed ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... focused on cancer patients, today announced a new partnership with the International ... this rare type of non-Hodgkin’s lymphoma, their families and physicians. , “Waldenstrom’s ...
(Date:10/13/2015)... ... October 13, 2015 , ... HealthAware , headquartered ... Patient Engagement Summit . HealthAware is a technology company focused on the ... interventions via mobile devices that provide a framework for the development of healthy ...
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... Symposium ... for the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, ... place immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , ...
(Date:10/13/2015)... ... 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood , ... The research, which was conducted at the Dental Institute at King's College London in ... stress during pregnancy and future dental health in the child. For years, researchers have ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Human Longevity, Inc. (HLI), ... of medicine, announced today the launch of the company,s ... that has the potential to transform healthcare. The inaugural ... CA , at HLI,s headquarters facility. More Health ... other US and International cities. ...
(Date:10/13/2015)... , Oct. 13, 2015  Synapse Biomedical Inc. ( ... Approval Study (PAS) studying the use of the NeuRx ... continuing to enroll patients. the United ... the FDA market-approved criteria. The PAS study group met ... 2014. The study has since expanded the enrollment target ...
(Date:10/13/2015)... Oct. 13 2015 ... of the "US & European Markets ... (2010-2021)" report to their offering. ... addition of the "US & European ... Countries (2010-2021)" report to their offering. ...
Breaking Medicine Technology: